S-Equol
ZNCBIO is a professional S-Equol China supplier and manufacturer, we have rich experience for exporting. Please be sure to email us at info@zncbio.com when you have any demands.
CAS No.: 531-95-3
TYPE: JP GRADE & USP GRADE
BRAND: ZNCBIO
MOQ: 20 KGS
Introduction of S-Equol
S-Equol (S-(-)-Equol) is a high-purity, bioactive isoflavan metabolite naturally converted from soy daidzein via specific human intestinal flora. Notably, only 50%–65% of East Asian populations can synthesize endogenous S-Equol, while most people cannot obtain sufficient active ingredients simply by consuming soy foods. As a natural selective estrogen receptor modulator (SERM), it features high affinity for estrogen receptor β (ERβ) and minimal stimulation on breast and uterine-related ERα, ensuring mild and safe bidirectional endocrine regulation.
It effectively alleviates common menopausal discomforts including hot flashes, night sweats, insomnia and mood fluctuations, and relieves premenstrual syndrome such as breast tenderness and irritability. Additionally, it inhibits bone resorption to maintain bone density, exerts potent antioxidant effects to delay skin aging, and reduces DHT production to support male prostate health and improve androgenic alopecia. Commercially sourced from safe microbial fermentation, S-Equol is a reliable, GRAS-certified nutritional ingredient for daily hormone balance and whole-body wellness care.
Basic Information of S-Equol
| Empirical Formula (Hill Notation): | C15H14O3 |
|---|---|
| CAS Number: | 531-95-3 |
| Molecular Weight: | 242.27 |
| NACRES: | NA.77 |
| Assay: | ≥97% (HPLC) |
| Form: | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | −20°C |
Function of S-Equol
The health benefits of S‑Equol mainly stem from the fact that it is a bioactive metabolite produced by gut bacteria from daidzein, a major isoflavone found in soy. Because its molecular structure resembles human estrogen, it can bind to estrogen receptors and trigger a range of specific biological effects. Importantly, S‑Equol is the naturally occurring and biologically active enantiomer, whereas R‑Equol is essentially inactive.
Its potential benefits are summarized below.
Bone Health
This is one of the most extensively studied benefits of S‑Equol, particularly in relation to skeletal health.
Core mechanism: S‑Equol acts as a high‑affinity agonist for estrogen receptor beta (ERβ). In bone tissue, activating ERβ helps inhibit bone resorption, reduce oxidative stress, and dampen inflammatory responses, thereby protecting the bone microarchitecture. Unlike activation of estrogen receptor alpha (ERα), ERβ activation is not considered to carry the same risks of carcinogenesis or thrombosis.
Research evidence: In animal models of estrogen deficiency (mimicking postmenopausal status in women), S‑Equol has been shown to improve trabecular bone volume by 10–20% and increase trabecular number. Some human trials have also demonstrated that daily intake of 10 mg of S‑Equol can reduce bone resorption markers by approximately 20%.
Cardiovascular Protection
Core mechanism: S‑Equol exerts protective effects against myocardial ischemia‑reperfusion injury by activating the PI3K/Akt signaling pathway. In simpler terms, this protection helps reduce the additional damage that heart muscle may suffer when blood flow is restored after a period of ischemia, thereby improving cardiac contractile function.
Menopausal Symptoms
Alleviation of hot flashes and joint pain: S‑Equol is often used to relieve menopausal symptoms caused by declining estrogen levels, such as hot flashes and joint pain. This is also why S‑Equol‑containing supplements are sometimes used by individuals to manage side effects associated with hormone therapy.
Other Potential Benefits
Based on its estrogen‑like activity as well as its antioxidant and anti‑inflammatory properties, S‑Equol has also shown promise in other areas, including:
Skin health and anti‑aging: Some studies suggest it may slow skin aging by increasing collagen and elastin content in the skin, or by acting as an antioxidant.
Metabolic health and prostate health: Preliminary research indicates it may have beneficial effects on metabolic syndrome, and it may also inhibit the proliferation of androgen‑driven prostate cancer cells by suppressing the production of dihydrotestosterone (DHT).
Important Reminders
Individual variation in “producer” status: Not everyone can fully benefit from dietary soy consumption. Research indicates that only about 30% to 50% of people harbor the specific gut bacteria capable of converting daidzein into S‑Equol – these individuals are referred to as “Equol producers.” Whether or not you produce Equol is a critical factor determining whether you can obtain the above‑mentioned benefits.
Safety and risks: Although S‑Equol is generally considered a relatively safe dietary supplement, it still possesses estrogenic activity. In certain contexts, it may affect the proliferation of hormone‑sensitive cancer cells (e.g., certain breast cancer cells). Therefore, before taking any S‑Equol‑containing supplement – especially for individuals with a history of or risk for hormone‑related cancers – it is essential to consult a qualified healthcare professional.
Summary
In summary, S‑Equol acts as a selective estrogen receptor modulator and shows potential benefits for bone, cardiovascular, and menopausal health. However, its efficacy varies among individuals due to differences in gut microbiota composition, and there are safety considerations that must not be overlooked. Therefore, it should not be used blindly as a supplement.
Application of S-Equol
S‑Equol, as a highly bioactive metabolite of soy isoflavones produced by gut microbiota, is seeing its application areas expand from traditional uses to multiple health directions. Current research reveals that its value lies in acting as a high‑affinity selective agonist for estrogen receptor beta (ERβ) , enabling it to exert beneficial estrogen‑like effects while avoiding some of the risks associated with ERα.
Based on available research, the main application areas of S‑Equol can be summarized as follows.
Hormone‑Related Health Management
This is the most established area of S‑Equol application, particularly for conditions linked to changes in estrogen levels.
Alleviation of menopausal symptoms: This is the most thoroughly researched area. Studies have confirmed that S‑Equol‑containing supplements can effectively relieve menopausal symptoms caused by declining estrogen levels, such as hot flashes and joint pain. Consequently, some patients experiencing these side effects from hormonal therapy medications also use S‑Equol to improve their symptoms. A key drug‑interaction study has provided safety data in this regard: daily supplementation with 10 mg of S‑Equol does not produce clinically meaningful effects on the blood concentrations of common breast cancer hormonal therapies (such as letrozole, tamoxifen, etc.).
Bone health maintenance: This is one of the most promising applications of S‑Equol and is considered an example of “precision nutrition.” Its core mechanism involves inhibiting bone resorption, exerting antioxidant effects, and reducing inflammation through ERβ activation. In animal models of estrogen deficiency, it has been shown to improve trabecular bone volume by 10–20%. Limited human trial data also indicate that 10 mg of S‑Equol per day can reduce bone resorption markers by approximately 20%.
Prostate health maintenance: According to the U.S. National Cancer Institute (NCI), S‑Equol can inhibit the production of dihydrotestosterone (DHT) and may thereby suppress the proliferation of androgen‑driven prostate cancer cells. This positions it as a potential candidate for prostate health management.
Cardiovascular Protection
The cardiovascular protective effects of S‑Equol have also attracted attention. A 2024 study published in the journal Steroids confirmed that in an isolated male rat heart model, S‑Equol significantly improved cardiac contractile function following myocardial ischemia‑reperfusion injury by activating the PI3K/Akt signaling pathway. This suggests its potential as an adjunctive therapeutic agent to mitigate myocardial damage during procedures such as cardiac surgery.
Cognitive and Neuroprotection
Frontier research is exploring the benefits of S‑Equol for the brain. Clinical studies have suggested that women who naturally produce S‑Equol perform better cognitively compared to non‑producers, with the potential mechanism possibly linked to the neuroprotective effects of ERβ agonists.
Skin Health and Cosmetics
S‑Equol is also being developed as an active ingredient in functional cosmetics. Although the potency of some of its effects is debated compared to other analogues, its anti‑inflammatory, antioxidant, and estrogen‑like activities still make it a candidate compound with promise for improving skin health and slowing skin aging.
The Key Behind Application Potential: Individual Variability
It is worth emphasizing that the application of S‑Equol is highly individualized, because its precursor (daidzein) requires specific gut bacteria for conversion. Studies show that only about 25–60% of people across different populations are “Equol producers.” This means that whether one can derive the benefits of S‑Equol from consuming soy largely depends on the individual’s gut microbiota composition – which also explains why clinical trial results on soy isoflavones have often been inconsistent. Therefore, direct supplementation with S‑Equol may be an effective strategy to bypass this limitation and achieve its precise application.
Summary and Reminders
In summary, the application areas of S‑Equol are expanding from traditional women’s health (menopause, bone) to cardiovascular, neurological, and skin health, showcasing its potential as a multifunctional bioactive compound. The core logic of its application lies in achieving tissue‑specific beneficial modulation through selective activation of ERβ.
However, despite its broad promise, most research remains at the preclinical or early‑clinical stage. Its long‑term safety across different fields, optimal dosages, and definitive efficacy in diverse populations still require validation through more high‑quality clinical trials. In particular, for individuals with a history of or risk for hormone‑sensitive cancers, consultation with a qualified healthcare professional is essential before using any related supplements.
Dosage & Administration Of S-Equol
Recommended Daily Dosage
Menopausal relief (hot flashes, night sweats, insomnia): 10 mg daily; severe symptoms can take 15–20 mg temporarily, then switch back to 10 mg for maintenance.
PMS care: 10 mg per day, take 7–10 days before menstruation, pause during period.
Bone & skin anti-aging maintenance: 5–10 mg daily for long-term use.
Men’s prostate & hair loss support: 10 mg daily.
Mild daily hormone balance: low dose 5 mg per day.
Usage Instructions
Take with meals or after meals with warm water; dietary fat boosts absorption. Avoid empty stomach to prevent mild stomach upset.
≤10 mg: once daily after dinner to ease night sweat and sleep issues.
15–20 mg high dose: split into morning and evening doses.
Intake Cycle
Noticeable improvement on hot flashes and mood after 4–8 consecutive weeks. For bone density, skin and hair care, continuous intake over 3 months is recommended. No physical dependence; symptoms will not rebound sharply after discontinuation.
Synergistic Combinations
Menopause & bone health: S-Equol + Calcium + Vitamin D3+K2
Anti-aging skin care: S-Equol + Collagen + Anthocyanins
Male hair & prostate care: S-Equol + Saw Palmetto
PMS relief: S-Equol + Evening Primrose Oil
Precautions
Max daily intake shall not exceed 20 mg; excess may cause slight dizziness and flatulence.
Not suitable for people with estrogen-related tumors, pregnant, breastfeeding or trying-to-conceive women. Keep a 2-hour interval if taking hormone medicines.
Contact Details
SHANGHAI ZNCBIO
Side Effects And Contraindications For S-Equol
S-Equol demonstrates a generally favorable safety profile at standard dosages, with side effects typically being mild, reversible gastrointestinal issues or transient breast tenderness.
However, due to its estrogen-like activity, it is strictly contraindicated for individuals with estrogen-dependent diseases. Below is a detailed breakdown of the underlying mechanisms of its side effects and the clinical criteria for identifying contraindicated populations.
Detailed Mechanisms and Clinical Observations of Side Effects
Gastrointestinal Reactions: Occurring in approximately 5% to 10% of users, symptoms mainly include mild bloating, nausea, or altered bowel habits. The mechanism relates to S-Equol acting as a plant-derived active molecule that alters local microecology or stimulates gastrointestinal smooth muscle in the gut. These symptoms typically resolve on their own within 1 to 2 weeks of continuous use as the gut microbiome adapts.
Breast Tissue Responses: A very small number of sensitive individuals may experience breast tenderness or mild distension. This occurs because, although S-Equol has a high affinity for Estrogen Receptor beta (ERβ), it still exhibits a very weak cross-reactivity with Estrogen Receptor alpha (ERα), causing slight edema in breast ducts or glandular tissues.
Skin Allergies and Rashes: These are extremely rare and are generally associated with inactive excipients (such as fillers or coating materials) in the supplement, rather than the pharmacological toxicity of S-Equol itself.
Pathophysiological Assessment of Contraindicated Populations
Absolute Contraindications (High-Risk Groups):
History of Hormone-Dependent Tumors: This includes patients with active or previously treated breast cancer, endometrial cancer, or ovarian cancer. The pathogenesis of these diseases is closely linked to the overactivation of estrogen signaling pathways (especially ERα). Any exogenous intake of estrogen-like substances could act as a potential stimulus for tumor recurrence.
Pregnancy and Lactation: S-Equol can cross the placental barrier or enter breast milk. Exogenous estrogen-like substances may interfere with the normal development of the fetal reproductive system or disrupt the infant’s endocrine homeostasis through breast milk.
Relative Contraindications (Populations Requiring Clinical Monitoring)
Benign Hormone-Sensitive Conditions: Such as severe uterine fibroids, breast hyperplasia with atypical hyperplasia, or endometriosis. Although S-Equol is relatively safe, it may exacerbate congestion or edema in existing lesions and must be used with caution under a doctor’s evaluation.
Individuals with Coagulation Disorders: S-Equol has a mild antiplatelet aggregation effect. When used concomitantly with anticoagulants or antiplatelet drugs like warfarin or aspirin, it can synergistically increase the risk of subcutaneous bleeding, epistaxis, or even internal bleeding.
Patients with Severe Hepatic or Renal Insufficiency: S-Equol is metabolized in the liver via the cytochrome P450 enzyme system and excreted by the kidneys. Severe impairment of liver or kidney function can reduce its clearance rate, leading to systemic accumulation and placing additional strain on these organs.
In summary, the risk of side effects associated with S-Equol primarily depends on an individual’s underlying health status and gut metabolic characteristics. Before initiating a supplementation regimen, it is imperative to strictly screen for contraindications and proceed with dose titration and safety monitoring under professional guidance.
More Product Recommendations
Shanghai ZNC Biotechnology Co., Ltd.(ZNCBIO) is a supplier of various chemicals and packaging materials. In addition to S-Equol， it can also provide you with products in many fields such as nutritional supplements, food additives, APIs, cosmetics and minerals.
